On March 10, 2020 POINT Biopharma Inc. reported that it has entered into an agreement with SCINTOMICS GmbH for the exclusive use and development of a family of more than seventy patented next generation PSMA radioligands for targeted radiotherapy of prostate cancer (Press release, Point Biopharma, MAR 10, 2020, View Source [SID1234561513]). Under the terms of the agreement, POINT has acquired both North American and broad international rights to the compounds. SCINTOMICS is eligible to receive milestone payments and royalties over the life of the collaboration.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement of this acquisition complements POINT Biopharma’s PNT 2002 clinical program set to begin in 2020.

According to Michael Gottlieb, POINT Biopharma’s Chief Commercial Officer, "The breadth of this acquisition provides POINT with a clear strategic pathway of patient focused differentiation. POINT is committed to novel treatments and continued innovation of radiopharmaceutical assets."

Joe McCann, POINT Biopharma CEO adds, "We are excited to bring these compounds to patients. We anticipate commencement of a phase 1/2 clinical program in 2021."

Saskia Kropf, SCINTOMICS CEO stated, "We are delighted that in POINT Biopharma we have found an excellent partner for the clinical development of this unique targeting technology. We are certain that in the experienced leadership team from North America and Europe, POINT is well equipped to make this innovative radioligand therapy rapidly accessible to prostate cancer patients."

Dr. Vikas Prasad, (Vice Chair and Senior Physician Department of Nuclear Medicine University Hospital of Ulm Germany) a scientific advisor to POINT Biopharma adds, "Radiomolecular compounds for prostate cancer diagnosis and treatment have been used in Germany for many years with much success. They are positioned to revolutionize the global treatment landscape for patients around the world."

On March 10, 2020 Cantargia AB reported the acquisition of a patent portfolio from Cellerant Therapeutics Inc covering aspects around the interleukin 1 receptor accessory protein (IL1RAP) (Press release, , MAR 10, 2020, View Source [SID1234638816]). The acquired IP includes a US patent on IL1RAP as a target for antibody therapy in leukemia. Thereby, Cantargia has broadened its IP portfolio and secured ownership of the key patents around IL1RAP as a target for cancer therapy.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cantargia develops antibody-based pharmaceuticals against the interleukin 1 receptor accessory protein (IL1RAP). In the most advanced program, the antibody CAN04 binds IL1RAP with high affinity and its anti-tumor activity consists of stimulation of immune cells to eradicate cancer cells as well as blockade of interleukin 1 signaling. CAN04 is being investigated in an open label phase I/IIa clinical trial, CANFOUR, examining first line chemotherapy combination with two different standard regimes in patients with non-small cell lung cancer (NSCLC) or pancreatic cancer (PDAC), as well as monotherapy in late stage patients (www.clinicaltrials.gov).

Cantargia has a broad patent protection, including IP on the antibody CAN04 valid until 2035, and other IL1RAP binding antibodies. In addition, Cantargia also has patents on antibody therapy targeting IL1RAP in both solid tumors and in hematological cancer. Besides the patents that Cantargia already owns, there is one additional patent on IL1RAP as target for antibody-based therapy in hematological cancer: US patent no. 8,715,619 from Cellerant, valid until 2029. Although hematological cancer is outside Cantargia’s current development focus, Cantargia has now acquired this and remaining patents and patent applications in this family as well as some additional IP from Cellerant’s IL1RAP portfolio. The additional IP concerns a few novel antibodies against IL1RAP that may be further evaluated in Cantargias CANxx program. Under the terms of the agreement, Cellerant will receive an insignificant upfront purchase payment and will also be entitled to a low single digit royalty on sales covered by claims in the acquired Cellerant patents, until they expire. No other milestone payment is included in the agreement.

"Cantargia has focused the CAN04 development on solid tumors and the clinical data we have generated in patients with NSCLC or PDAC are encouraging. By acquiring this IP, we have secured all relevant IP on IL1RAP as a target for cancer therapy", said Göran Forsberg, CEO of Cantargia.

On March 10, 2020 HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform, reported that it will release fourth quarter and full year 2019 financial results before the market opens on Thursday, March 19, 2020 (Press release, Hookipa Pharma, MAR 10, 2020, View Source [SID1234555364]). Following the release, the Company will host a live conference call and webcast at 8:00 a.m. EDT to discuss its financial results and corporate update.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live conference call, please dial +1-631-510-7495 (from the US) or +44-207-1 92-8000 (international) and refer to conference ID 1769733. A live audio webcast of the event will also be available within the Investors & Media section of HOOKIPA’s website at View Source An archived replay will be accessible for 30 days following the event.

On March 10, 200 AngioDynamics, Inc. (NASDAQ: ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, reported that it will report financial results for the third quarter of fiscal year 2020 before the market open on Tuesday, April 7, 2020 (Press release, AngioDynamics, MAR 10, 2020, View Source [SID1234555380]). The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international) and refer to the passcode 13700177.

This conference call will also be webcast and can be accessed from the "Investors" section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available from 11:00 a.m. ET on Tuesday, April 7, 2020, until 11:59 p.m. ET on Tuesday, April 14, 2020. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13700177.

On March 10, 2020 IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTCQB: IPATF) reported financial results for its fiscal year 2020 third quarter ended January 31, 2020 (Press release, ImmunoPrecise Antibodies, MAR 10, 2020, View Source [SID1234555365]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Revenue. The Company posted a quarterly revenue of $4,034,440, an increase of 50% from the year-ago quarter and an all-time record. The increasing revenue trend is due to growth in both the volume and financial value of client contracts. Revenue outlook is positive for the fourth quarter.

Gross Margin. During the three months ended January 31, 2020, the Company achieved a gross profit of $2,223,669.

Net Loss. The Company reported a record low for net loss of $625,837, during the three months ended January 31, 2020, representing a decrease of 47% in net loss from the year-ago quarter. The decrease in net loss is due to a $655,614 increase in gross profit, as well as recognized cost synergies resulting in lower spend, offset by higher non-cash amortization of intangible assets, depreciation of leased assets as a result of implementing IFRS 16, Leases.

Non-IFRS Measures*. For the first time in the Company’s history, Adjusted EBITDA for the quarter and the nine-month period ending January 31, 2020, was positive, at $717,716 and $18,356, respectively, compared to ($461,353) and ($1,553,090) for the same periods last year. The positive Adjusted EBITDA is a result of the third quarter’s 50% increase in revenue and lower adjusted operating expenses compared to the prior year’s quarter and nine-month period.

"We are pleased to report IPA’s record quarterly revenue and earnings, which was fueled by strong demand for a wide variety of our products and services in tool, research and therapeutic antibody discovery and manufacturing," said Jennifer Bath, IPA’s President and CEO. "Careful attention to operational prioritization, site efficiencies and brand recognition in 2019 led to new vendor qualifications from pharmaceutical and biotech companies, enabling larger allocations of corporate budgets in the 2020 calendar year. This past quarter is a powerful testament to the satisfaction and engagement of our clients, and the realization of leveraged synergies globally."

Recent ImmunoPrecise Highlights:

• IPA Launched Coronavirus Vaccine and Therapeutic Programs
• As IPA Directs R&D Efforts Toward Coronavirus, Company is Added to WHO Draft Landscape of Companies Combating COVID-19
• Company Announced AI Collaboration with EVQLV, Inc., to Accelerate the Efforts in the Development of a Coronavirus Therapeutic
• IPA Integrated SGI’s DNA Automated DNA Printer at Utrecht Site
• IPA Subsidiary, UPE, Joining Genmab and Merus in Expansion to New Biotech Accelerator in the Center of European Science Industry

IPA periodically provides information for investors on its corporate website, ImmunoPrecise.com. This includes press releases and other information on financial performance, reports filed or furnished with the TSX, information on corporate governance and details related to its annual meeting of shareholders. Reports filed or furnished with the TSX can be found at sedar.com.